Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02364713 · ClinicalTrials.gov registry record · Phase 2
MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer
A Phase 2 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT02364713: Clinical Trial Phase 2 study, sponsored by Mayo Clinic.
NCT02364713 is a Phase 2 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02364713, a Phase 2 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well oncolytic measles virus encoding thyroidal sodium iodide symporter (MV-NIS) compared to investigator's choice chemotherapy works in treating patients with ovarian, fallopian, or peritoneal cancer. Measles virus, which has been changed in a certain way, may be able to kill tumor cells without damaging normal cells.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Paclitaxel
- BIOLOGICAL Bevacizumab
- DRUG Gemcitabine Hydrochloride
- BIOLOGICAL Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2015-03-13 |
| Est. Completion | 2022-01-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02364713
The ClinicalTrials.gov registry entry for NCT02364713 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02364713 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02364713 about?
NCT02364713 is a clinical study titled "MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer". This randomized phase II trial studies how well oncolytic measles virus encoding thyroidal sodium iodide symporter (MV-NIS) compared to investigator's choice chemotherapy works in treating patients with ovarian, fallopian, or peritoneal cancer. Measles virus, which has been changed in a certain way,...
What is the current status of trial NCT02364713?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2015-03-13. Estimated completion is 2022-01-13.
What interventions are being tested in trial NCT02364713?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Paclitaxel (DRUG), Bevacizumab (BIOLOGICAL), Gemcitabine Hydrochloride (DRUG), Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter (BIOLOGICAL).
Who is sponsoring clinical trial NCT02364713?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.